Rigel Pharmaceuticals Inc
RIGL· Nasdaq
Released Aug 2, 2022, after the close
10-Q filed Aug 2, 2022, 33 days after period end · 0001558370-22-011638
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $29.82M | $26.27M | $16.02M | $10.41M |
| Net Income | -$13.49M | -$13.82M | -$17.58M | -$20.61M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.08 |
| -$0.10 |
| -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.